Literature DB >> 26954340

Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov.

Agnes Dechartres1, Carolina Riveros2, Michael Harroch3, Timor Faber2, Philippe Ravaud1.   

Abstract

Mesh:

Year:  2016        PMID: 26954340     DOI: 10.1001/jamainternmed.2016.0137

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  6 in total

1.  Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov.

Authors:  Isaretta L Riley; L Ebony Boulware; Jie-Lena Sun; Karen Chiswell; Loretta G Que; Monica Kraft; Jamie L Todd; Scott M Palmer; Monique L Anderson
Journal:  Clin Trials       Date:  2017-11-10       Impact factor: 2.486

2.  Trends of Clinical Trials for Drug Development in Rare Diseases.

Authors:  Ryuichi Sakate; Akiko Fukagawa; Yuri Takagaki; Hanayuki Okura; Akifumi Matsuyama
Journal:  Curr Clin Pharmacol       Date:  2018

3.  Current status and trend of clinical development of orphan drugs in China.

Authors:  Ziling Xiang; Wengao Jiang; Bo Yan; Junhao Jiang; Hang Zheng
Journal:  Orphanet J Rare Dis       Date:  2022-07-27       Impact factor: 4.303

4.  Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases.

Authors:  Giuseppe Traversa; Lucia Masiero; Luciano Sagliocca; Francesco Trotta
Journal:  Orphanet J Rare Dis       Date:  2016-04-12       Impact factor: 4.123

5.  Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis.

Authors:  Christopher W Jones; Michelle R Safferman; Amanda C Adams; Timothy F Platts-Mills
Journal:  BMJ Open       Date:  2017-10-11       Impact factor: 2.692

6.  Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.

Authors:  Chris A Rees; Natalie Pica; Michael C Monuteaux; Florence T Bourgeois
Journal:  PLoS Med       Date:  2019-11-21       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.